Omniscan (Gadodiamide)

Omniscan is a gadolinium‑based contrast agent used in magnetic resonance imaging to highlight anatomical details.

• Central nervous system imaging: improves detection of lesions, tumors, and vascular abnormalities.
• Cardiovascular MRI: enhances visualization of cardiac chambers, blood flow, and myocardial perfusion.
• Whole‑body and oncologic MRI: aids in identifying metastatic disease and assessing tumor vascularity.

• Gadodiamide is a gadolinium‑based chelate that shortens the T1 relaxation time of nearby water protons when administered intravenously. This property increases signal intensity on T1‑weighted MRI sequences, providing clearer contrast between vascular and extravascular tissues and allowing detailed anatomical assessment.

Adverse reactions to Omniscan are generally related to its intravenous administration and gadolinium content.

Common Side Effects

• Nausea: mild, transient episodes reported.
• Headache: occasional, resolves without intervention.
• Injection site discomfort: mild pain or burning at the infusion site.
• Warm sensation: brief feeling of warmth during injection.
• Dizziness: transient light‑headedness in some patients.
• Metallic taste: temporary metallic sensation in the mouth.

Serious or Rare Side Effects

• Nephrogenic systemic fibrosis (NSF): fibrotic skin changes in patients with severe renal impairment.
• Anaphylactoid reactions: hives, bronchospasm, or hypotension requiring emergency care.
• Severe hypersensitivity: angio‑edema or respiratory distress.
• Cardiac arrest: extremely rare but reported in hypersensitive individuals.
• Renal toxicity: acute kidney injury in predisposed patients.
• Death: rare fatal outcomes linked to severe anaphylaxis or NSF.

When using Omniscan, clinicians should assess patient risk factors and monitor for adverse events.

• Renal function assessment: evaluate glomerular filtration rate before administration.
• History of allergies: review prior reactions to contrast media.
• Pregnancy considerations: use only if essential, after risk‑benefit analysis.
• Pediatric use: adjust dosing based on weight and monitor closely.
• Concomitant nephrotoxic drugs: avoid or use with caution.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Omniscan may interact with other agents that affect renal function or immune response.

Major Interactions (Avoid)

• Metformin: increased risk of lactic acidosis in renal impairment.
• High‑dose iodinated contrast: combined nephrotoxicity risk.\n- Loop‑diuretics: may exacerbate renal insufficiency.

Moderate Interactions (Monitor Closely):

• Non‑steroidal anti‑inflammatory ​​  ​  ​  ​  ​  ​  ​  ​  ​  ...  

-   -  .